Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

The versatile nature of miR-9/9* in human cancer.

Nowek K, Wiemer EAC, Jongen-Lavrencic M.

Oncotarget. 2018 Apr 17;9(29):20838-20854. doi: 10.18632/oncotarget.24889. eCollection 2018 Apr 17. Review.

2.

Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP.

Hatzl S, Geiger O, Kuepper MK, Caraffini V, Seime T, Furlan T, Nussbaumer E, Wieser R, Pichler M, Scheideler M, Nowek K, Jongen-Lavrencic M, Quehenberger F, Wölfler A, Troppmair J, Sill H, Zebisch A.

Cancer Res. 2016 Jun 15;76(12):3644-54. doi: 10.1158/0008-5472.CAN-15-3049. Epub 2016 Apr 15.

3.

Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age.

Nowek K, Sun SM, Dijkstra MK, Bullinger L, Döhner H, Erkeland SJ, Löwenberg B, Jongen-Lavrencic M.

Leukemia. 2016 Feb;30(2):303-9. doi: 10.1038/leu.2015.282. Epub 2015 Oct 14.

PMID:
26464168
4.

Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG.

Nowek K, Sun SM, Bullinger L, Bindels EM, Exalto C, Dijkstra MK, van Lom K, Döhner H, Erkeland SJ, Löwenberg B, Jongen-Lavrencic M.

Leukemia. 2016 Jan;30(1):229-37. doi: 10.1038/leu.2015.183. Epub 2015 Jul 15.

PMID:
26174629

Supplemental Content

Support Center